新股消息 | 思摩爾國際公開發售超購逾115倍,超過18萬人認購
uSMART友信智投7月3日消息,全球最大的電子霧化設備製造商思摩爾國際已於今日中午截止公開招股。市場消息透露,其已錄得115倍超額認購,凍結資金逾1000億元,有逾18萬人認購。
根據回撥機制,當公開發售認購倍數達到55倍以上時,公開發售股數比例將由12%增加到37%,即回撥後甲乙組將分別獲配約10.6萬手。根據過往經驗,1手中簽率可能在30%左右。
其招股價範圍是9.6-12.4元,此前彭博報導,思摩爾計畫以上限12.4港元定價。
思摩爾將於9日(週四)公佈中簽結果,10日上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.